Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › irinotecan

irinotecan

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of irinotecan

145 trials tracked of irinotecan: 22 in phase 3 or 4 and 11 with published results. The most-cited published study has 1127 citations.

145Trials tracked
22Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 2 Phase 3 20 Phase 2 106 Phase 1 17
  1. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Completed · 1,127 cited
  2. Phase 3 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer Completed · 592 cited
  3. Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Completed · 567 cited
  4. Phase 3 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Completed · 501 cited
  5. Phase 3 A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 325 cited
  6. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 195 cited
Show 44 more trials
  1. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma Completed · 181 cited
  2. Phase 3 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study Completed · 55 cited
  3. Phase 3 Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer Completed · 48 cited
  4. Phase 4 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed · 18 cited
  5. Phase 3 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed · 1 cited
  6. Phase 4 A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum Completed
  7. Phase 3 Colorectal Cancer Metastatic Completed
  8. Phase 3 A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer Completed
  9. Phase 3 Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Completed
  10. Phase 3 Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer Completed
  11. Phase 3 A Study in Second Line Metastatic Colorectal Cancer Completed
  12. Phase 3 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma Completed
  13. Phase 3 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed
  14. Phase 3 Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Completed
  15. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  16. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  17. Phase 2 Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Completed
  18. Phase 2 Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Completed
  19. Phase 2 A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer Completed
  20. Phase 2 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Completed
  21. Phase 2 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer Completed
  22. Phase 2 Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer Completed
  23. Phase 2 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer Completed
  24. Phase 2 Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab Completed
  25. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  26. Phase 2 A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI Completed
  27. Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed
  28. Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Completed
  29. Phase 2 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Completed
  30. Phase 2 Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer Completed
  31. Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma Completed
  32. Phase 2 ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer Completed
  33. Phase 2 Irinotecan Study For Cervical Cancer Completed
  34. Phase 2 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed
  35. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
  36. Phase 2 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach Completed
  37. Phase 2 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
  38. Phase 2 A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer Completed
  39. Phase 2 Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery Completed
  40. Phase 2 Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer Completed
  41. Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Completed
  42. Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
  43. Phase 2 Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas Completed
  44. Phase 2 Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Completed

Showing the 50 most-cited and recently-updated of 145 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse
Rheumatology Sys. Review
Long-Surviving PDAC With HRR Alterations May Face CNS Sanctuary Relapse Long Survival in Pancreatic Cancer Can Bring Brain Spread
This case report describes a 51-year-old man with metastatic pancreatic ductal adenocarcinoma who survived 30 months from diagnosis and 3.5 …
A single case shows pancreatic cancer that responds to treatment may later reach the brain, even after 30 months.
Frontiers Oct 12, 2026
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer
Oncology Meta-analysis
Immune classical transcriptomic subtype correlates with superior survival in metastatic pancreatic cancer Transcriptomic Signatures May Help Predict Pancreatic Cancer Outcomes
This retrospective pooled analysis of phase 2 trials evaluates transcriptomic signatures and GemPred status in patients with metastatic panc…
New research suggests that specific genetic markers in pancreatic cancer may help predict how well different chemotherapy treatments will wo…
Oct 10, 2026
Etoposide plus cisplatin produces substantial but temporary regression in metastatic prostatic small cell neuroendocrine carcinoma
Urology Sys. Review
Etoposide plus cisplatin produces substantial but temporary regression in metastatic prostatic small cell neuroendocrine carcinoma Surgery and Chemotherapy Provide Temporary Relief for Prostate Cancer
This case report describes a patient with de novo metastatic prostatic small cell neuroendocrine carcinoma treated with etoposide plus cispl…
A specific chemotherapy combination and surgery can shrink tumors and relieve urinary blockage in a rare form of prostate cancer.
Frontiers Sep 17, 2026
Evaluating High-Dose Vitamin D3 Supplementation in Metastatic Colorectal Cancer Treatment Regimens
Gastroenterology RCT
Evaluating High-Dose Vitamin D3 Supplementation in Metastatic Colorectal Cancer Treatment Regimens Testing High Dose Vitamin D3 for Patients with Metastatic Colorectal Cancer
A Phase 3 trial assessed if high-dose vitamin D3 improves outcomes in mCRC patients receiving bevacizumab-based chemotherapy.
Doctors tested if adding high doses of vitamin D3 to standard chemotherapy helped patients with advanced colon cancer live longer.
JAMA Sep 2, 2026
Etoposide plus cisplatin shows higher treatment completion rate of 89.0% vs. 74.1% in HGNEC
Pulmonology & Critical Care RCT
Etoposide plus cisplatin shows higher treatment completion rate of 89.0% vs. 74.1% in HGNEC Trial Shows Etoposide and Cisplatin for Neuroendocrine Lung Carcinoma
This post hoc analysis of a Phase III trial evaluated 217 patients with high-grade neuroendocrine carcinoma of the lung who underwent comple…
A trial of 217 patients with lung cancer found that higher doses of certain chemotherapy drugs did not lead to better outcomes.
Sep 2, 2026
Irinotecan plus cisplatin shows no RFS benefit over etoposide plus cisplatin in resected lung HGNEC
Pulmonology & Critical Care RCT
Irinotecan plus cisplatin shows no RFS benefit over etoposide plus cisplatin in resected lung HGNEC Five-year follow-up shows irinotecan plus cisplatin matches etoposide plus cisplatin for lung cancer survival
This randomized, open-label, phase III study compared irinotecan plus cisplatin to etoposide plus cisplatin in 221 patients with resected hi…
A five-year look at lung cancer patients found that irinotecan plus cisplatin worked just as well as etoposide plus cisplatin for keeping th…
Jun 1, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Oncology RCT
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Apr 28, 2026
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
Oncology Cohort
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort Most patients on strong pancreatic cancer chemo needed a dose change
This cohort study included 514 patients with pancreatic ductal adenocarcinoma treated at UCSF oncology clinics.
Over 60% of patients with pancreatic cancer needed a dose adjustment during treatment with FOLFIRINOX at UCSF clinics.
medRxiv Apr 28, 2026
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
Oncology RCT
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Apr 16, 2026
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer
Geriatrics & Aging Phase II
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer New Drug Combo Helps Older Pancreatic Cancer Patients Live Longer
This Phase II multicentric study evaluated adapted-dose FOLFIRINOX in 72 elderly patients (aged 70 years or older) with metastatic pancreati…
A new drug mix helps older pancreatic cancer patients live longer while keeping them active, provided doctors check specific genes first to …
CT.gov Apr 16, 2026

All irinotecan Articles